Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 332

1.

JAK-2 mutations and their relevance to myeloproliferative disease.

Levine RL, Gilliland DG.

Curr Opin Hematol. 2007 Jan;14(1):43-7. Review.

PMID:
17133099
2.

Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.

Pikman Y, Levine RL.

Curr Opin Oncol. 2007 Nov;19(6):628-34. Review.

PMID:
17906464
3.

JAK and MPL mutations in myeloid malignancies.

Tefferi A.

Leuk Lymphoma. 2008 Mar;49(3):388-97. doi: 10.1080/10428190801895360. Review.

PMID:
18297515
4.

[Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].

Rajnai H, Bödör C, Reiniger L, Timár B, Csernus B, Szepesi A, Csomor J, Matolcsy A.

Orv Hetil. 2006 Nov 12;147(45):2175-9. Hungarian.

PMID:
17402211
5.

MPL W515L mutation in Chinese patients with myeloproliferative diseases.

Xu W, Li JY, Xia J, Zhang SJ, Fan L, Qiao C.

Leuk Lymphoma. 2008 May;49(5):955-8. doi: 10.1080/10428190802035966.

PMID:
18464114
6.

JAK2 kinase inhibitors and myeloproliferative disorders.

Chen AT, Prchal JT.

Curr Opin Hematol. 2010 Mar;17(2):110-6. doi: 10.1097/MOH.0b013e3283366b91. Review.

PMID:
20087176
7.

Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders.

Levine RL, Wernig G.

Hematology Am Soc Hematol Educ Program. 2006:233-9, 510. Review.

PMID:
17124066
8.
9.

JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.

Kilpivaara O, Levine RL.

Leukemia. 2008 Oct;22(10):1813-7. doi: 10.1038/leu.2008.229. Epub 2008 Aug 28. Review.

PMID:
18754026
10.

JAK2 mutations and clinical practice in myeloproliferative neoplasms.

Tefferi A.

Cancer J. 2007 Nov-Dec;13(6):366-71. Review.

PMID:
18032973
11.

JAK2 and MPL mutations in myeloproliferative neoplasms.

Koppikar P, Levine RL.

Acta Haematol. 2008;119(4):218-25. doi: 10.1159/000140634. Epub 2008 Jun 20. Review.

PMID:
18566540
12.

A role for JAK2 mutations in myeloproliferative diseases.

Morgan KJ, Gilliland DG.

Annu Rev Med. 2008;59:213-22. Review.

PMID:
17919086
13.

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.

Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, DeAngelo DJ, Clark JJ, Lee SJ, Golub TR, Wadleigh M, Gilliland DG, Levine RL.

PLoS Med. 2006 Jul;3(7):e270.

14.

Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.

Levine RL, Pardanani A, Tefferi A, Gilliland DG.

Nat Rev Cancer. 2007 Sep;7(9):673-83. Review.

PMID:
17721432
15.

The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity.

James C, Mazurier F, Dupont S, Chaligne R, Lamrissi-Garcia I, Tulliez M, Lippert E, Mahon FX, Pasquet JM, Etienne G, Delhommeau F, Giraudier S, Vainchenker W, de Verneuil H.

Blood. 2008 Sep 15;112(6):2429-38. doi: 10.1182/blood-2008-02-137877. Epub 2008 Jul 8.

16.

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.

Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G, Finke C, Mak CC, Mesa R, Zhu H, Soll R, Gilliland DG, Tefferi A.

Leukemia. 2007 Aug;21(8):1658-68. Epub 2007 May 31.

PMID:
17541402
17.

Mechanisms of mutations in myeloproliferative neoplasms.

Levine RL.

Best Pract Res Clin Haematol. 2009 Dec;22(4):489-94. doi: 10.1016/j.beha.2009.08.006. Review.

PMID:
19959098
18.

New insights into the pathogenesis and treatment of chronic myeloproliferative disorders.

Mesa RA.

Curr Opin Hematol. 2008 Mar;15(2):121-6. doi: 10.1097/MOH.0b013e3282f3debd. Review.

PMID:
18300758
19.

JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms.

Siemiatkowska A, Bieniaszewska M, Hellmann A, Limon J.

Leuk Res. 2010 Mar;34(3):387-9. doi: 10.1016/j.leukres.2009.06.017. Epub 2009 Jul 29.

PMID:
19643476
20.

Myeloproliferative disorders.

Levine RL, Gilliland DG.

Blood. 2008 Sep 15;112(6):2190-8. doi: 10.1182/blood-2008-03-077966. Review.

Supplemental Content

Support Center